sur Biophytis (EPA:ALBPS)
Biophytis Reports 2024 Financial Results and Strategy for 2025
Biophytis has announced its financial results for 2024 and outlined strategic plans for 2025. The company's revenue remained at zero, with the net loss decreasing to €10.4 million, a reduction from the previous year's €17 million. R&D expenses were cut by €5.4 million. As of December 31, the company had €78k in cash, a significant drop from €5.6 million in 2023. Recent funding measures raised €2.5 million and €2.6 million, providing a financial runway until September 2025.
Strategic initiatives include initiating a Phase 2 obesity study and a Phase 3 sarcopenia trial. Biophytis aims to leverage partnerships to fund these studies. The company also plans to enhance its drug discovery platform, incorporating AI and novel technologies to accelerate research.
The planned studies target critical markets in the US, Europe, Asia, and Brazil. A partnership with Blanver in Latin America exemplifies Biophytis' funding strategy.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Biophytis